Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation

Cytokines, Cellular and Molecular Therapy

Volumn 4, Issue 3, 1998, Pages 161-167

  Nagler, Arnon ^a,b   Bishara, Amal ^a   Brautbar, Chaim ^a   Barak, Vivian ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogeneic bone marrow transplantation; Cytokines; Graft rejection; Graft versus host disease

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD LEVEL; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HLA-C ANTIGENS; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0031665305     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Beatty PG, Dahlberg S, Michelson EM et al, Probability of finding HLA-matched unrelated marrow donors. Transplantation (1988) 45: 714-18.
2. Westoff CF, Fertility in the United States. Science (1986) 234: 554-9.
3. Slavin S, Nagler A, New developments in bone marrow transplantation. Curr Opin Oncol (1991) 3: 254-71.
4. Gale RP, Bortin MM, Van Bekkum DW et al, Risk factors for acute graft-versus-host disease. Br J Haematol (1987) 67: 397-406.
5. Ferrara JL, Deeg HJ, Graft-versus-host disease. N Engl J Med (1991) 324: 667-74.
6. Anasetti C, Amos D, Beatty PG et al, Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med (1989) 320: 197-204.
7. Anasetti C, Beatty PG, Storb R et al, Effect of HLA incompatibility on graft-versus-host disease, relapse and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol (1990) 29: 79-91.
8. Vowels MR, Lam PO, Tang R et al, Bone marrow transplantation in children using closely matched related and unrelated donors. Bone Marrow Transplant (1991) 8: 87-92.
9. Kernan NA, Bartsch G, Ash RC et al, Analysis of 462 transplantations from unrelated donors facilitated by the National Bone Marrow Donor Program. N Engl J Med (1993) 328: 593-602.
10. McGlave P, Bartsch G, Anasetti C et al, Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the national marrow donor program. Blood (1993) 81: 543-550.
11. Beatty PG, Hansen JA, Longton GM et al, Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation (1991) 51: 443-7.
12. Marks DI, Cullis JO, Ward KN et al, Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first 2 years. Ann Intern Med (1993) 119: 207-14.
13. Aversa F, Tabilio A, Terenzi A et al, Successful engraftment of T-cell-depleted haploidentical 'three-loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood (1994) 84: 3948-55.
14. Bozdech MJ, Sondel PM, Trigg ME et al, Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection. Exp Hematol (1985) 13: 1201-10.
15. Van Bekkum DW, The double barrier in bone marrow transplantation. Semin Hematol (1974) 11: 325-340.
16. Uharek L, Gassmann W, Glass B et al, Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood (1992) 79: 1612-21.
17. Nagler A, Barak V, Slavin S, The role of cytokines in graft-versus-host reactions/bone marrow rejections. In: Human Cytokines: Their Role in Disease and Therapy (ed RK Purie, BB Aggarwal) 153-61. Blackwell, Oxford, 1995.
18. Antin JH, Ferrara JM, Cytokine dysregulation and acute graft-versus-host disease Blood (1992) 80: 2964-8.
19. Barak V, Levi-Schaffer F, Nisman B, Nagler A, Cytokine dysregulation m chronic graft versus host disease Leuk Lymphoma (1995) 17: 169-73.
20. Holler H, Kolb HJ, Moller A et al, Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood (1990) 75: 1011-16.
21. Symington FW, Pepe MS, Chen AB, Deliganis A, Serum tumor necrosis factor alpha associated with acute graft-versus-host disease in humans. Transplantation (1990) 50: 518-21
22. Symington FW, Symington RE, Liu PY et al, The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation (1992) 54: 457-62.
23. Nagler A, Or R, Nisman B et al, Elevated inflammatory cytokine levels in bone marrow graft rejection. Transplantation (1995) 60: 943-8.
24. Toren A, Novick D, Or R et al, Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation. Transplantation (1996) 62: 138-42.
25. Doutrelepont JM, Moser M, Leo O et al, Hyper IgE in stimulatory graft-versus-host disease: role of interleukin 4. Clin Exp Immunol (1991) 83: 133-6.
26. McCarthy PL, Abhyanhan S, Neben S et al, Inhibition of interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood (1991) 78: 1915-18
27. Ushiyama C, Hirano T, Miyajima H et al, Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. J Immunol (1995) 154: 2687-96.
28. Herve P, Flesch M, Tiberghien P et al, Phase I-II trial of a monoclonal anti-TNF-alpha antibody (B-C7) in the treatment of refractory severe acute GVHD. Blood (1992) 79: 3362-7.
29. Umland SP, Razac S, Nahrebne DK, Seymour BW, Effects of in vivo administration of interferon (IFN)-gamma, anti-IFN-gamma, or anti-interleukin-4 monoclonal antibodies in chronic autoimmune graft-versus-host disease. Clin Immunol Immunopathol (1986) 47: 371-80.
30. Sykes M, Szot GL, Nguyen PL, Pearson DA, Interleukin-12 inhibits graft-versus-host disease. Blood (1995) 86: 2429-38.
31. Terasaki PI, Bernoco D, Park MS et al, Microdroplet testing for HLA-A, -B, -C and -D antigens. Am J Clin Pathol (1991) 2: 55-62.
32. Petersdorf EW, Smith AG, Haase AM et al, Polymorphism of HLA-DRw52-associated DRBI genes as defined by sequence-specific oligonucleotide probe hybridization and sequencing. Tissue Antigens (1991) 38: 169-77.
33. Dupont B, Hansen JA, Human mixed lymphocyte culture reaction genetics, specificity and biological implication. Adv Immunol (1991) 27: 1481-6.
34. Browning MJ, Krausa P, Rowan A et al, Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotypes and surface expression on colorectal tumor cells lines. Proc Natl Acad Sci USA (1993) 90: 2842-5.
35. Glucksberg H, Storb R, Fefer A et al, Clinical manifestations of graft-versus-host reaction (GvHR) in human recipients of marrow from HLA-matched sibling donors. Transplantation (1974) 18: 295-304.
36. Lerner KG, Kao GF, Storb R et al, Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HLA-matched sibling donors. Transplant Proc (1974) 6: 367-71.
37. Waldmann H, Polliack A, Hale G et al, Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (campath-1). Lancet (1984) ii: 483-6.
38. Van Leeuwen JEM, Van Tol MJ, Bodzinga BG et al, Detection of mixed chimaerism in flow sorted cell subpopulations by PCR-amplified VNTR markers after allogeneic bone marrow transplantation. Br J Haematol (1991) 79: 218-25.
39. Dixon WJ, Massey Jr FJ, Introduction to Statistical Analysis, 4th edn, 121-30. McGraw-Hill, New York, 1967.
40. Bishara A, Amar A, Brautbar C et al, The putative role of HLA-C recognition in graft versus host disease (GVHD) and graft rejection after unrelated bone marrow transplantation (BMT). Exp Hematol (1995) 23: 1667-75
41. Nagler A, Brautbar C, Slavin S et al, Bone marrow transplantation using unrelated and family donors: the impact of HLA-C disparity. Bone Marrow Transplant (1996) 18: 891-7.
42. Krenger W, Ferrara JLM, Dysregulation of cytokines during graft-versus-host disease. J Hematother (1996) 5: 3-14.
43. Tong J, Viale M, Bacigalupo A et al, Cytokine serum levels and acute graft versus host disease after allogeneic bone marrow transplantation. Hematologica (1992) 77: 365-6.
44. Jadus MR, Wepsic HT, The role of cytokines in graft versus host reactions and disease. Bone Marrow Transplant (1992) 10: 1-14.
45. Parkman R, Lenarsky C, Santos R et al, Cytokines during acute graft-versus-host disease (GVHD) following matched unrelated donor (MUD) transplantation. Blood (1991) 78: 286 (abst 1135).
46. Schwaighofer H, Herold M, Schwartz T et al, Serum levels of interleukin 6, interleukin 8 and C-reactive protein after human allogeneic bone marrow transplantation. Transplantation (1994) 58: 430-6.
47. Schwaighofer H, Kernan NA, O'Reilly RS et al, Serum levels of cytokines and secondary messages after T-cell-depleted and non-T-cell-depleted bone marrow transplantation. Transplantation (1996) 62: 947-53.
48. Niederwieser D, Herold M, Woloszczuk W et al, Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation (1990) 50: 620-5.
49. Niederwieser D, Aubock J, Hajek-Rosenmayr A et al, The role of cytokines and MHC antigens in human GVHD: analysis of T-cell specificities and endogenous cytobine levels. Bone Marrow Transplant (1989) 4(Suppl 2): 84-88.
50. Antin JH, Weinstein HJ, Guinan EC et al, Recombinant human interleukin-1 receptor antagonist in die treatment of steroid-resistant graft versus host disease. Blood (1993) 81: 2394-9.
51. Sahdev I, O'Reilly R, Hoffman MK, Correlations between interleukin-1 production and engraftment of transplanted bone marrow stem cells in patients with lethal immunodeficiencies. Blood (1989) 73: 1712-19.
52. De Waal Malefyt R, Hannen J, Spits H et al, Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via down regulation of class n major histocompatibility complex expression. J Exp Med (1991) 174: 915-24.
53. De Waal Malefyt R, Abrams JS, Bennett B et al, Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of TL-10 produced by monocytes. J Exp Med (1991) 174: 1209-20.
54. Rus V, Svetic A, Nguyen P et al, Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. J Immunol (1995) 155: 2396-406.
55. Trinchieri G, Scott P, The role of interleukin 12 in the immune response, disease and therapy. Immunol Today (1994) 15: 460-3.
56. Hsieh CS, Macatonia SE, Tripp CS et al, Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science (1993) 260: 547-9.
57. Carpenter CB, The cellular basis of allograft rejections. Immunol Today (1981) 2: 50-5.
58. Herve P, Wijdenes J, Bergerat JP et al, Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood (1990) 75: 1017-23.
59. Malilay GP, Sevenich EA, Filipovich AH, Prevention of graft rejection in allogeneic bone marrow transplantation. Transplantation (1990) 50: 406-10.
60. Kozak RW, Fitzgerald DP, Atcher RW et al, Selective elimination in vitro of alloresponsive T cells to human transplantation antigens by toxin or radionucleotide conjugated anti-IL-2 receptor (Tac) monoclonal antibody. J Immunol (1990) 144: 3417-23.